Toggle Main Menu Toggle Search

Open Access padlockePrints

BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups

Lookup NU author(s): Dr Venetia BigleyORCiD, Professor Matthew CollinORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Langerhans cell histiocytosis (LCH) is a clonal disorder with elusive etiology, characterized by the accumulation of CD207(+) dendritic cells (DCs) in inflammatory lesions. Recurrent BRAF-V600E mutations have been reported in LCH. In this study, lesions from 100 patients were genotyped, and 64% carried the BRAF-V600E mutation within infiltrating CD207(+) DCs. BRAF-V600E expression in tissue DCs did not define specific clinical risk groups but was associated with increased risk of recurrence. Strikingly, we found that patients with active, high-risk LCH also carried BRAF-V600E in circulating CD11c(+) and CD14(+) fractions and in bone marrow (BM) CD34(+) hematopoietic cell progenitors, whereas the mutation was restricted to lesional CD207(+) DC in low-risk LCH patients. Importantly, BRAF-V600E expression in DCs was sufficient to drive LCH-like disease in mice. Consistent with our findings in humans, expression of BRAF-V600E in BM DC progenitors recapitulated many features of the human high-risk LCH, whereas BRAF-V600E expression in differentiated DCs more closely resembled low-risk LCH. We therefore propose classification of LCH as a myeloid neoplasia and hypothesize that high-risk LCH arises from somatic mutation of a hematopoietic progenitor, whereas low-risk disease arises from somatic mutation of tissue-restricted precursor DCs.


Publication metadata

Author(s): Berres ML, Lim KPH, Peters T, Price J, Takizawa H, Salmon H, Idoyaga J, Ruzo A, Lupo PJ, Hicks MJ, Shih A, Simko SJ, Abhyankar H, Chakraborty R, Leboeuf M, Beltrao M, Lira SA, Heym KM, Bigley V, Collin M, Manz MG, McClain K, Merad M, Allen CE

Publication type: Article

Publication status: Published

Journal: Journal of Experimental Medicine

Year: 2014

Volume: 211

Issue: 4

Pages: 669-683

Print publication date: 17/03/2014

ISSN (print): 0022-1007

ISSN (electronic): 1540-9538

Publisher: Rockefeller University Press

URL: http://dx.doi.org/10.1084/jem.20130977

DOI: 10.1084/jem.20130977


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
ASH Scholar Award
Histiocytosis Association
Baylor College of Medicine Junior Faculty Seed Grant
HistioCure Foundation (Texas Children's Cancer Center Histiocytosis Program)
Texas Children's Hospital Pediatric Pilot Award
University of Zurich Clinical Research Program
BE 4818/1-1German Research Association (Deutsche Forschungsgemeinschaft)
CA090433NIH K12
CA154947ANIH R01
AI089987NIH R01
AI10008NIH R01
CA154489NIH R01
P50CA126752NIH SPORE in Lymphoma

Share